3[3]Moyer LA,Mast EE.Hepatitis B:virology,epidemiology,disease,and prevention and an overview of viral hepatitis.Am J Prey Med,1994,10 (suppl):45-55. 被引量：1
4[4]World Health Organization Department of Communicable Disease Surveillance and Response.Hepatitis B-an introduction.Available at:www.who.int/ emc-documents/ hepatitis/ docs/ whocdscsrlyo20022/ introduction/ introduction.html.Last update:January,2005.Accessed May 5,2005. 被引量：1
5[5]Cihlar T,Lin DC,Pritchard JB,Fuller MD,Mendel DB,Sweet DH.The antivirul nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.Mol Pharmacol,1999,56:570-580. 被引量：1
7[7]Marcellin P.Adefovir dipivoxil for the treatment of hepatitis B e antigenposititive chronic hepatitis B.N Engl J Med,2003,348:808-816. 被引量：1
8[8]Santantonio T,Mazzola M,Iacovazzi T,Miglietta A,Guastadisegni A,Pastore G.Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine.J Hepatol,2000,32:300-306. 被引量：1
9[9]Tassopoulos NC,Volpes R,Pastore G,et al.Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.Lamivudine Precore Mutant Study Group.Hepatology,1999,29:889-896. 被引量：1
10[10]Food and Drug Administration Center of Drug Evaluation.And Research.Approval Letter:BaracludeTM Available at:www.fda.gov/cder/foi/appletter/2005/021797,021798ltr,pdf.Last update:2005.Accessed 2005. 被引量：1
